CFM
LAB icon

Catalyst Funds Management’s Standard BioTools LAB Stock Holding History

Catalyst Funds Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.2K Buy
+110,795
New +$105K 0.01% 616

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Catalyst Funds Management's LAB Position: Q2 2026 in Review

Catalyst Funds Management opened a new position in Standard BioTools (LAB) in Q2 2026: 110,795 shares worth $91.2K. The stake represents 0.01% of the portfolio and ranks #616 among its holdings.

144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Catalyst Funds Management held 110,795 shares of Standard BioTools worth $91.2K as of Q2 2026.
  • Standard BioTools was a new Catalyst Funds Management position in Q2 2026.
  • Standard BioTools made up 0.01% of Catalyst Funds Management's portfolio in Q2 2026, its #616 holding.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.